Deal-Making

Emergent taking $180m hit as US Gov scraps CDMO contract

The US Department of Health and Human Services has terminated a long-term CDMO partnership with Emergent BioSolutions, which included a $628 million deal to produce COVID-19 vaccines. In 2012, Emergent BioSolutions entered into a public-private partnership for pandemic preparedness with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services (HHS). When COVID-19 hit, the partnership was expanded with Emergent receiving $628 million as part of the federal government’s pandemic response Operation…

Vaccine partnership results in optimized mRNA process, says BioNet

BioNet’s product development of genetic vaccine know-how integrated with BIA’s chromatographic columns for mRNA purification has produced a high-yield mRNA process, says firm. BioNet is a French-Thai biotech firm that focuses on manufacturing genetically engineered vaccines and BIA Separations is a biochromatography development and manufacturing company, which Sartorius acquired in October 2020 for $423 million. The collaboration, which was formed in early 2021, has resulted in what the firms are calling a successful development of an optimized messenger RNA (mRNA)…

Lonza bags Codiak’s exosome plant in $65m deal

Lonza has acquired an exosome manufacturing facility in Lexington, Massachusetts from Codiak BioSciences, which will keep its pipeline of therapeutic candidates. “Exosomes are extracellular vesicles excreted by cells into the surrounding fluids with a diameter between 30 and 150 nanometers,” Senthil Ramaswamy, executive director of Cell and Gene Technologies R&D, Lonza told us. “They represent a form of cell-to-cell communication. Cells can exchange metabolites, genetic information, and proteins through exosomes. The membrane-bound structure of exosomes allows for loading with various…

ElevateBio adds genome engineering tech with Life Edit buy

Life Edit’s genome editing capabilities will be combined with ElevateBio’s cell and gene enabling technologies to expand the number of therapeutic uses. The deal, of which financial details have not been disclosed, sees cell and gene therapy (CGT) tech firm ElevateBio acquire all of AgBiome’s shares of Life Edit Therapeutics (Life Edit). According to ElevateBio, the acquisition will allow the firm to integrate Life Edit’s genome editing abilities with its induced pluripotent stem cells (iPSCs), viral vector, and cellular engineering platforms.…

Ecolab to acquire Purolite in $3.7bn deal

Ecolab adds service solutions to drive end-product safety and quality through the acquisition of Purolite, which it says doubles its existing high growth. Ecolab, a firm that specializes in water, hygiene and infection prevention solutions and services has entered into an agreement to buy Purolite, a separation tech company in a cash transaction valued at $3.7 billion. The transaction is expected to close in Q4 2021 and according to Ecolab, Purolite will operate as a separate global business unit but…

Autolomous and Vineti partner to deliver end-to-end solutions in CGT space

Autolomous will combine its manufacturing management systems with Vineti’s Personalized Therapy Management (PTM) platform to form an end-to-end cell and gene therapy pathway. The partnership between Autolomous and Vineti, two technology solution providers for cell and gene therapy (CGT) supply chains, aims to drive the visibility and exchange of information between stakeholders across the CGT value chain to ensure the companies can respond to unpredictable variables that occur with biological processes. According to Autolomous, the integration of the technologies will…

BioNTech eyes mid-2022 to build mRNA facility in Africa

BioNTech has struck a deal with Rwanda and Senegal to begin building a mRNA vaccine production plant in Africa next year. The decision to start building a messenger RNA (mRNA) plant next summer comes after the German biotech signed a memorandum of understanding (MoU) with the Rwandan government and Institut Pasteur de Dakar in Senegal this week. The firm had previously expressed the possibility of setting up mRNA manufacturing facilities on its own, or with partners in Africa and according…

NorthX Biologics takes over Charles River Swedish plant

NorthX Biologics will take over Charles River’s manufacturing facility in Matfors, Sweden through $52 million acquisition. Seven months on from Charles River Laboratories $875 million acquisition of Cognate Bio (Cognate acquired Cobra Biologics in November 2019) the firm has offloaded one of its Cognate assets, selling a plant in Matfors, Sweden to private investor group Flerie Invest in an acquisition worth $52 million. The entity has been named North X Biologics and the 7,000 square-meter facility houses process development and…

Joint research agreement to develop viral vector tech, says Matica Bio

Matica Bio and Sartorius have entered a joint research agreement to develop advanced viral vector manufacturing technology. Matica Biotechnology, a contract development manufacturing organization (CDMO) that specializes in the clinical and commercial production of cell and gene therapies (CGTs), will work on various studies with German life sciences firm Sartorius to streamline and optimize PAT technologies, automation software, and single-use platforms offered by Sartorius for large scale vector production. According to Matica, together both companies will tackle the challenges associated…

Hansoh goes for GOLD in siRNA partnership

Hansoh Pharma will use Silence Therapeutics’ mRNAi GOLD platform to develop three undisclosed short interfering ribonucleic acids (siRNAs). According to RNA interference biotech company Silence, its mRNAi GOLD platform is  “designed to accurately target and ‘silence’ specific disease-associated genes in liver cells by using the body’s natural process of RNA interference (RNAi).” Under the terms of the agreement, Hansoh will have the exclusive option to license rights to two targets in Hong Kong, Greater China, Macau, and Taiwan following Phase…